Abstract European Journal of Cardio-thoracic Surgery 31 (2007) 714—718 Operative complications and early mortality after induction therapy for lung cancer§ Federico Venuta *, Marco Anile, Daniele Diso, Mohsen Ibrahim, Tiziano De Giacomo, Matilde Rolla, Valeria Liparulo, Giorgio F. Coloni Cattedra di Chirurgia Toracica, Policlinico Umberto I, Universita` di Roma ‘‘La Sapienza’’, V.le del Policlinico, 00100 Rome, Italy Received 28 September 2006; received in revised form 20 December 2006; accepted 15 January 2007 Objective: Induction therapy for advanced lung cancer allows improvement of completeness of resection and survival. However, predictive risk factors for postoperative complications and early mortality remain controversial. We report ...
AbstractObjectives: Patients receiving induction therapy may have increased risk of morbidity and mo...
The recently reported experiences by Doddoli [1], Novoa [2], Martin [3] and Voltolini [4], add usefu...
Fourteen patients with primary bronchogenic carcinoma, including 6 stage IIIA patients and 7 IIIB di...
ObjectiveWe previously reported a high mortality after induction therapy and pneumonectomy for non-s...
IntroductionA main drawback of neoadjuvant chemotherapy is that it may increase operative morbidity ...
Objectives: The purpose of this study was to evaluate the risk of lung cancer surgery following indu...
ObjectiveUse and operative results of neoadjuvant therapy before major elective resection for primar...
Controversial results of surgical treatment after induction chemotherapy, especially in relation to ...
BackgroundIn clinical stage IIIA non–small cell lung cancer, the role of surgical resection, particu...
ABSTRACT: Controversial results of surgical treatment after induction chemotherapy, especially in re...
ObjectiveThe impact of induction chemotherapy on postoperative complications after pneumonectomy rem...
IntroductionPneumonectomy (PN) after induction chemotherapy (CT) for non-small cell lung cancer is c...
BackgroundPrior data indicate increased perioperative morbidity and mortality in patients receiving ...
Objective: The impact of induction chemotherapy on postoperative complications after pneumonectomy r...
In our clinic 212 patients with primary lung cancer had undergone lung resection during 12 years fro...
AbstractObjectives: Patients receiving induction therapy may have increased risk of morbidity and mo...
The recently reported experiences by Doddoli [1], Novoa [2], Martin [3] and Voltolini [4], add usefu...
Fourteen patients with primary bronchogenic carcinoma, including 6 stage IIIA patients and 7 IIIB di...
ObjectiveWe previously reported a high mortality after induction therapy and pneumonectomy for non-s...
IntroductionA main drawback of neoadjuvant chemotherapy is that it may increase operative morbidity ...
Objectives: The purpose of this study was to evaluate the risk of lung cancer surgery following indu...
ObjectiveUse and operative results of neoadjuvant therapy before major elective resection for primar...
Controversial results of surgical treatment after induction chemotherapy, especially in relation to ...
BackgroundIn clinical stage IIIA non–small cell lung cancer, the role of surgical resection, particu...
ABSTRACT: Controversial results of surgical treatment after induction chemotherapy, especially in re...
ObjectiveThe impact of induction chemotherapy on postoperative complications after pneumonectomy rem...
IntroductionPneumonectomy (PN) after induction chemotherapy (CT) for non-small cell lung cancer is c...
BackgroundPrior data indicate increased perioperative morbidity and mortality in patients receiving ...
Objective: The impact of induction chemotherapy on postoperative complications after pneumonectomy r...
In our clinic 212 patients with primary lung cancer had undergone lung resection during 12 years fro...
AbstractObjectives: Patients receiving induction therapy may have increased risk of morbidity and mo...
The recently reported experiences by Doddoli [1], Novoa [2], Martin [3] and Voltolini [4], add usefu...
Fourteen patients with primary bronchogenic carcinoma, including 6 stage IIIA patients and 7 IIIB di...